Other N-Methyl-D-Aspartate (NMDA) Receptor Antagonists with a Rapid Onset of Action and Less Side Effect in the Treatment of Depression
Journal of the Korean Society of Biological Psychiatry
;
: 149-154, 2015.
Article
Dans Coréen
| WPRIM
| ID: wpr-725356
ABSTRACT
Mood disorder is a common psychiatric illness with a high lifetime prevalence in the general population. Many prescribed antidepressants modulate monoamine neurotransmitters including serotonin, norepinephrine and dopamine. There has been greater focus on the major excitatory neurotransmitter in the human brain, glutamate, in the pathophysiology and treatment of major depressive disorder (MDD). Recently, ketamine, an N-methyl-D-aspartate receptor antagonist, has received attention and has been investigated for clinical trials and neurobiological studies. In this article, we will review the clinical evidence for glutamatergic dysfunction in MDD, the progress with ketamine as a rapidly acting antidepressant, and other N-methyl-D-aspartate receptor antagonist for treatment-resistant depression.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Encéphale
/
Dopamine
/
Sérotonine
/
Norépinéphrine
/
Prévalence
/
N-Méthyl-aspartate
/
Agents neuromédiateurs
/
Acide glutamique
/
Troubles de l'humeur
/
Dépression
Type d'étude:
Étude de prévalence
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Society of Biological Psychiatry
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS